Batefenterol has been used in trials studying the treatment of Pulmonary Disease, Chronic Obstructive.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aclidinium | The risk or severity of adverse effects can be increased when Batefenterol is combined with Aclidinium. |
| Mianserin | Mianserin may increase the anticholinergic activities of Batefenterol. |
| Mirabegron | The risk or severity of urinary retention can be increased when Batefenterol is combined with Mirabegron. |
| Potassium chloride | The risk or severity of gastrointestinal ulceration can be increased when Batefenterol is combined with Potassium chloride. |
| Pramlintide | The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Batefenterol. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Batefenterol. |
| Tiotropium | The risk or severity of adverse effects can be increased when Batefenterol is combined with Tiotropium. |
| Topiramate | The risk or severity of hyperthermia and oligohydrosis can be increased when Batefenterol is combined with Topiramate. |
| Umeclidinium | The risk or severity of adverse effects can be increased when Batefenterol is combined with Umeclidinium. |
| Benzylpenicilloyl polylysine | Batefenterol may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Spironolactone | The therapeutic efficacy of Batefenterol can be decreased when used in combination with Spironolactone. |
| Flunisolide | The risk or severity of hypokalemia can be increased when Flunisolide is combined with Batefenterol. |
| Beclomethasone dipropionate | The risk or severity of hypokalemia can be increased when Beclomethasone dipropionate is combined with Batefenterol. |
| Betamethasone | The risk or severity of hypokalemia can be increased when Betamethasone is combined with Batefenterol. |
| Fluticasone propionate | The risk or severity of hypokalemia can be increased when Fluticasone propionate is combined with Batefenterol. |
| Fluocinolone acetonide | The risk or severity of hypokalemia can be increased when Fluocinolone acetonide is combined with Batefenterol. |
| Triamcinolone | The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Batefenterol. |
| Prednisone | The risk or severity of hypokalemia can be increased when Prednisone is combined with Batefenterol. |
| Fludrocortisone | The risk or severity of hypokalemia can be increased when Fludrocortisone is combined with Batefenterol. |
| Hydrocortisone | The risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Batefenterol. |
| Prednisolone | The risk or severity of hypokalemia can be increased when Prednisolone is combined with Batefenterol. |
| Methylprednisolone | The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Batefenterol. |
| Trilostane | The risk or severity of hypokalemia can be increased when Trilostane is combined with Batefenterol. |
| Budesonide | The risk or severity of hypokalemia can be increased when Budesonide is combined with Batefenterol. |
| Dexamethasone | The risk or severity of hypokalemia can be increased when Dexamethasone is combined with Batefenterol. |
| Corticotropin | The risk or severity of hypokalemia can be increased when Corticotropin is combined with Batefenterol. |
| Cortisone acetate | The risk or severity of hypokalemia can be increased when Cortisone acetate is combined with Batefenterol. |
| Paramethasone | The risk or severity of hypokalemia can be increased when Paramethasone is combined with Batefenterol. |
| Ciclesonide | The risk or severity of hypokalemia can be increased when Ciclesonide is combined with Batefenterol. |
| Aldosterone | The risk or severity of hypokalemia can be increased when Aldosterone is combined with Batefenterol. |
| Fluticasone furoate | The risk or severity of hypokalemia can be increased when Fluticasone furoate is combined with Batefenterol. |
| Fluprednidene | The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Batefenterol. |
| Tixocortol | The risk or severity of hypokalemia can be increased when Tixocortol is combined with Batefenterol. |
| Fluprednisolone | The risk or severity of hypokalemia can be increased when Fluprednisolone is combined with Batefenterol. |
| Meprednisone | The risk or severity of hypokalemia can be increased when Meprednisone is combined with Batefenterol. |
| Dexamethasone isonicotinate | The risk or severity of hypokalemia can be increased when Dexamethasone isonicotinate is combined with Batefenterol. |
| Melengestrol | The risk or severity of hypokalemia can be increased when Melengestrol is combined with Batefenterol. |
| Deflazacort | The risk or severity of hypokalemia can be increased when Deflazacort is combined with Batefenterol. |
| Cortivazol | The risk or severity of hypokalemia can be increased when Cortivazol is combined with Batefenterol. |
| Prednylidene | The risk or severity of hypokalemia can be increased when Prednylidene is combined with Batefenterol. |
| Fluocortin | The risk or severity of hypokalemia can be increased when Fluocortin is combined with Batefenterol. |
| Fluperolone | The risk or severity of hypokalemia can be increased when Fluperolone is combined with Batefenterol. |
| Cloprednol | The risk or severity of hypokalemia can be increased when Cloprednol is combined with Batefenterol. |
| Fluclorolone | The risk or severity of hypokalemia can be increased when Fluclorolone is combined with Batefenterol. |
| Fluticasone | The risk or severity of hypokalemia can be increased when Fluticasone is combined with Batefenterol. |
| Mometasone furoate | The risk or severity of hypokalemia can be increased when Mometasone furoate is combined with Batefenterol. |
| Hydrocortisone acetate | The risk or severity of hypokalemia can be increased when Hydrocortisone acetate is combined with Batefenterol. |
| Hydrocortisone cypionate | The risk or severity of hypokalemia can be increased when Hydrocortisone cypionate is combined with Batefenterol. |
| Hydrocortisone succinate | The risk or severity of hypokalemia can be increased when Hydrocortisone succinate is combined with Batefenterol. |
| Prednisolone phosphate | The risk or severity of hypokalemia can be increased when Prednisolone phosphate is combined with Batefenterol. |
| Prednisolone hemisuccinate | The risk or severity of hypokalemia can be increased when Prednisolone hemisuccinate is combined with Batefenterol. |
| Methylprednisolone hemisuccinate | The risk or severity of hypokalemia can be increased when Methylprednisolone hemisuccinate is combined with Batefenterol. |
| Prednisone acetate | The risk or severity of hypokalemia can be increased when Prednisone acetate is combined with Batefenterol. |
| Clocortolone acetate | The risk or severity of hypokalemia can be increased when Clocortolone acetate is combined with Batefenterol. |
| Melengestrol acetate | The risk or severity of hypokalemia can be increased when Melengestrol acetate is combined with Batefenterol. |
| Betamethasone phosphate | The risk or severity of hypokalemia can be increased when Betamethasone phosphate is combined with Batefenterol. |
| Cortisone | The risk or severity of hypokalemia can be increased when Cortisone is combined with Batefenterol. |
| Clobetasol propionate | The risk or severity of hypokalemia can be increased when Clobetasol propionate is combined with Batefenterol. |
| Fluocinonide | The risk or severity of hypokalemia can be increased when Fluocinonide is combined with Batefenterol. |
| Hydrocortisone butyrate | The risk or severity of hypokalemia can be increased when Hydrocortisone butyrate is combined with Batefenterol. |
| Desoximetasone | The risk or severity of hypokalemia can be increased when Desoximetasone is combined with Batefenterol. |
| Mometasone | The risk or severity of hypokalemia can be increased when Mometasone is combined with Batefenterol. |
| Fluocortolone | The risk or severity of hypokalemia can be increased when Fluocortolone is combined with Batefenterol. |
| Prednisolone acetate | The risk or severity of hypokalemia can be increased when Prednisolone acetate is combined with Batefenterol. |
| Fluorometholone | The risk or severity of hypokalemia can be increased when Fluorometholone is combined with Batefenterol. |
| Difluocortolone | The risk or severity of hypokalemia can be increased when Difluocortolone is combined with Batefenterol. |
| Flumethasone | The risk or severity of hypokalemia can be increased when Flumethasone is combined with Batefenterol. |
| Methylprednisolone aceponate | The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Batefenterol. |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Batefenterol is combined with Glycopyrronium. |
| Atomoxetine | Atomoxetine may increase the tachycardic activities of Batefenterol. |
| Atosiban | The risk or severity of adverse effects can be increased when Batefenterol is combined with Atosiban. |
| Betahistine | The therapeutic efficacy of Batefenterol can be decreased when used in combination with Betahistine. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Batefenterol is combined with Botulinum toxin type A. |
| Glucagon | Batefenterol may increase the gastrointestinal motility reducing activities of Glucagon. |
| Sulpiride | Batefenterol may increase the anticholinergic activities of Sulpiride. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Batefenterol is combined with Botulinum toxin type B. |
| Eluxadoline | The risk or severity of constipation can be increased when Batefenterol is combined with Eluxadoline. |
| Ramosetron | The risk or severity of constipation can be increased when Batefenterol is combined with Ramosetron. |
| Naltrexone | The risk or severity of adverse effects can be increased when Batefenterol is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Batefenterol is combined with Bezitramide. |
| Tramadol | The risk or severity of adverse effects can be increased when Batefenterol is combined with Tramadol. |
| Morphine | The risk or severity of adverse effects can be increased when Batefenterol is combined with Morphine. |
| Codeine | The risk or severity of adverse effects can be increased when Batefenterol is combined with Codeine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Batefenterol is combined with Hydromorphone. |
| Methadone | The risk or severity of adverse effects can be increased when Batefenterol is combined with Methadone. |
| Meperidine | The risk or severity of adverse effects can be increased when Batefenterol is combined with Meperidine. |
| Oxycodone | The risk or severity of adverse effects can be increased when Batefenterol is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Batefenterol is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Batefenterol is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Batefenterol is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Batefenterol is combined with Sufentanil. |
| Alfentanil | The risk or severity of adverse effects can be increased when Batefenterol is combined with Alfentanil. |
| Fentanyl | The risk or severity of adverse effects can be increased when Batefenterol is combined with Fentanyl. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Batefenterol is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Batefenterol is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Batefenterol is combined with Remifentanil. |
| Buprenorphine | The risk or severity of adverse effects can be increased when Batefenterol is combined with Buprenorphine. |
| Hydrocodone | The risk or severity of adverse effects can be increased when Batefenterol is combined with Hydrocodone. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Batefenterol is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Batefenterol is combined with Oxymorphone. |